sacituzumab govitecan + tislelizumab

This drug combination consists of sacituzumab govitecan (Trodelvy) and tislelizumab (Tevimbra). Sacituzumab govitecan is a trophoblast cell-surface antigen 2 (Trop-2)-directed antibody-drug conjugate (ADC) that utilizes a hydrolyzable linker to deliver SN-38, a potent topoisomerase I inhibitor, directly to cancer cells. Tislelizumab is a humanized IgG4 monoclonal antibody designed to bind to the programmed cell death protein 1 (PD-1) receptor, thereby blocking its interaction with PD-L1 and PD-L2 to restore T-cell mediated anti-tumor immune responses. The combination is being investigated in the TREND-02 trial, sponsored by the First Hospital of China Medical University, as a neoadjuvant therapy for early-stage triple-negative breast cancer (TNBC). The rationale for the combination is based on the potential for the ADC to induce immunogenic cell death, which may synergize with the checkpoint inhibition provided by tislelizumab.

Brand names

Trodelvy + Tevimbra

Other names

sacituzumab govitecan plus tislelizumabSG plus tislelizumab